Camena Bioscience, a pioneer in enzymatic DNA synthesis producing complex, high-fidelity gene constructs for AI-driven antibody discovery, has appointed Gregory P. McGuinness as CEO.
McGuinness has over 30 years of executive leadership and operational expertise, having successfully commercialised disruptive and foundational technologies across the life sciences and diagnostics markets. His career has been defined by scaling operations, driving product innovation, and executing commercial expansion into global markets.
McGuinness was most recently CEO at Inanovate and was also CEO/Co-Founder at TwiXimo Therapeutics. He has previously held board and senior leadership positions, including Chief Commercial Officer at Genturi, Entrepreneur in Residence at Rose Ventures, VP of Business Development at DNA Electronics, VP International Operations at NimbleGen (acquired by Roche) and VP Commercial Operations at Genetic MicroSystems (acquired by Affymetrix).
McGuinness commented: “I look forward to working alongside our exceptionally talented team to build on the Company’s strong foundation, delivering the highest quality products to our clients, and driving our vision for the future of AI-driven antibody discovery.”
Dr Aditya Rajagopal, Chair of the Board, Camena Bioscience, added: “Greg’s track record in scaling high-potential technology companies makes him the ideal choice to drive Camena through its commercialisation phase. He brings the rare ability to guide complex technical developments while building world-class operational infrastructure.”